Compare CYTK & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | CELH |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 8.5B |
| IPO Year | 2004 | 2008 |
| Metric | CYTK | CELH |
|---|---|---|
| Price | $78.68 | $30.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 17 |
| Target Price | ★ $89.26 | $64.81 |
| AVG Volume (30 Days) | 1.7M | ★ 9.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.33 |
| Revenue | $13,368,000.00 | ★ $1,318,014,000.00 |
| Revenue This Year | $7.37 | $37.04 |
| Revenue Next Year | $310.19 | $9.89 |
| P/E Ratio | ★ N/A | $91.21 |
| Revenue Growth | N/A | ★ 101.65 |
| 52 Week Low | $31.99 | $27.47 |
| 52 Week High | $80.20 | $66.74 |
| Indicator | CYTK | CELH |
|---|---|---|
| Relative Strength Index (RSI) | 62.37 | 51.34 |
| Support Level | $59.07 | $27.56 |
| Resistance Level | $79.66 | $33.49 |
| Average True Range (ATR) | 3.20 | 1.60 |
| MACD | 0.51 | 0.31 |
| Stochastic Oscillator | 83.65 | 54.50 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Celsius Holdings operates in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. It owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.